-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCL-161 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCL-161 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LCL-161 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:LCL-161 is...
-
Company Insights
Atos SE – Digital Transformation Strategies
Atos Digital Transformation Strategies Overview Atos SE (Atos) is tapping into the power of key disruptive technologies to offer new products/services and achieve operational efficiency. AI, big data, cloud, cybersecurity, and IoT are among the key technologies under focus for the company. The annual ICT spending of Atos is estimated at $725.5 million for 2023. A major share of this spending is earmarked for acquiring software, ICT services, and hardware from vendors. Atos is a French IT company. It offers...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZND-5 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZND-5 in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZND-5 in Mantle Cell Lymphoma Drug Details: ZNd-5 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZND-5 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZND-5 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZND-5 in Follicular Lymphoma Drug Details: ZNd-5 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZND-5 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZND-5 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZND-5 in Marginal Zone B-cell Lymphoma Drug Details: ZNd-5...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZND-5 in Primary Systemic Amyloidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZND-5 in Primary Systemic Amyloidosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZND-5 in Primary Systemic Amyloidosis Drug Details: ZNd-5 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LK-101 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LK-101 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LK-101 in Small-Cell Lung Cancer Drug Details: Cell therapy is under...
-
Product Insights
Soft Tissue Biologics Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Soft Tissue Biologics Pipeline Market Report Overview Soft Tissue Biologics are used in surgical procedures to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. This model focuses on the repair of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), rotator cuff, and Achilles tendon. Other indications include medial collateral ligament (MCL), lateral collateral ligament (LCL), medial patellofemoral ligament (MPFL), ulnar collateral ligament (UCL), flexor tendon, and hip flexor repair. They...
-
Company Profile
Lucky Cement Ltd – Company Profile
Lucky Cement Ltd (LCL), a part of the Yunus Brothers Group, is a manufacturer and supplier of cement. Its cement manufacturing portfolio includes the Ordinary Portland Cement (OPC), clinkers, block cement, and the sulphate resistant cement. Lucky Cement markets products under different brand names such as Lucky Star, Lucky Gold, Lucky Cement (Regular), Lucky Raj, Lucky Block Cement, Lucky Supreme, and Lucky Sulphate Resistant Cement (SRC). The company also operates international production facilities in Iraq and Congo. The company has...
Add to Basket